Neurocrine Biosciences Inc (NBIX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Neurocrine Biosciences reported revenue of $2.86B, up 21.4% from $2.36B the year before. Net income was $478.6M (a 16.7% net margin), or $4.67 per diluted share. Gross margin was 98.2% and operating margin was 21.6%. Operating activities generated $782.7M of cash, leaving $748.7M of free cash flow. At fiscal year end, Neurocrine Biosciences held $4.63B in total assets against $1.38B in total liabilities, including $713.0M of cash and equivalents.
Open the full interactive Neurocrine Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Neurocrine Biosciences Key Stats
| Share Price | $135.13 |
|---|---|
| Market Cap | $14.08B |
| P/E Ratio | 28.9 |
| Revenue YoY Growth | +21.4% |
| 52-Week Range | $123.10 – $185.50 |
| Shares Outstanding | 101.0 million (basic, 2026 Q2) |
Neurocrine Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.05B | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Cost of Goods Sold | — | — | $23.2M | $39.7M | $34.0M | $52.1M |
| Gross Profit | — | — | $1.47B | $1.85B | $2.32B | $2.81B |
| Operating Income | $163.0M | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| Pre-Tax Income | $106.7M | $101.4M | $213.9M | $332.1M | $486.0M | $705.4M |
| Income Tax | -$300.6M | $11.8M | $59.4M | $82.4M | $144.7M | $226.8M |
| Net Income | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| Diluted EPS | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
Neurocrine Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $794.9M | $805.5M | $814.5M | $959.0M |
| Net Income | $209.5M | $153.7M | $197.9M | $144.4M |
| Diluted EPS | $2.04 | $1.50 | $1.91 | $1.39 |
Neurocrine Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $187.1M | $340.8M | $262.9M | $251.1M | $233.0M | $713.0M |
| Current Assets | $1.02B | $972.8M | $1.45B | $1.61B | $1.72B | $2.52B |
| Total Assets | $1.73B | $2.07B | $2.37B | $3.25B | $3.72B | $4.63B |
| Current Liabilities | $186.5M | $245.8M | $537.7M | $654.8M | $507.7M | $743.4M |
| Total Long-Term Debt | $317.9M | $335.1M | — | — | — | — |
| Total Liabilities | $608.5M | $698.5M | $660.9M | $1.02B | $1.13B | $1.38B |
| Shareholders' Equity | $1.13B | $1.37B | $1.71B | $2.23B | $2.59B | $3.25B |
Neurocrine Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $228.5M | $256.5M | $339.4M | $389.9M | $595.4M | $782.7M |
| Cash From Investing | $4.1M | -$130.2M | -$177.1M | -$467.1M | -$126.8M | -$264.4M |
| Cash From Financing | -$157.8M | $27.4M | -$234.3M | $65.3M | -$486.7M | -$38.3M |
| Free Cash Flow | $217.6M | $233.1M | $322.9M | $361.6M | $557.2M | $748.7M |
Figures from Neurocrine Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neurocrine Biosciences financials page for every line item.
Neurocrine Biosciences Company Profile
| Ticker | NBIX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000914475 |
Frequently Asked Questions
What was Neurocrine Biosciences' revenue in fiscal 2025?
Neurocrine Biosciences (NBIX) reported revenue of $2.86B for fiscal 2025.
What is Neurocrine Biosciences' annual revenue history?
Neurocrine Biosciences' annual revenue by fiscal year: 2020: $1.05B; 2021: $1.13B; 2022: $1.49B; 2023: $1.89B; 2024: $2.36B; 2025: $2.86B.
What was Neurocrine Biosciences' net income in fiscal 2025?
Neurocrine Biosciences reported net income of $478.6M for fiscal 2025.
What was Neurocrine Biosciences' earnings per share (EPS) in fiscal 2025?
Neurocrine Biosciences' diluted EPS was $4.67 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Neurocrine Biosciences generate in fiscal 2025?
Neurocrine Biosciences generated $748.7M of free cash flow in fiscal 2025.
What was Neurocrine Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Neurocrine Biosciences reported revenue of $959.0M.
How many shares of Neurocrine Biosciences are outstanding?
Neurocrine Biosciences reported a weighted average of 101.0 million basic shares outstanding in 2026 Q2.
What is Neurocrine Biosciences' market cap?
Based on its latest closing price, Neurocrine Biosciences (NBIX) has a market capitalization of about $14.08B.
When does Neurocrine Biosciences' fiscal year end?
Neurocrine Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Neurocrine Biosciences headquartered?
Neurocrine Biosciences lists its business address in San Diego, California in its SEC filings.
Neurocrine Biosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →